**What is already known about the topic?**

-   Delirium is a common, neuropsychiatric disorder that causes significant distress to patients and caregivers, affects patient quality of life, and leads to prolonged hospital stays and increased health care costs.

-   A 2013 systematic review revealed that delirium is highly prevalent in the acute inpatient palliative care setting, but the rate of occurrence in other palliative care settings such as the palliative care consultative setting, general inpatient setting, and community settings is not well understood.

-   There are many validated tools to screen for and diagnose delirium in palliative care patients; however, no consensus exists as to the optimal tools or diagnostic practices.

**What this paper adds?**

-   This paper also includes new estimates of delirium occurrence in general inpatient settings, palliative care consultative settings, and community settings.

-   This review is the first to conduct a meta-analysis of delirium prevalence in palliative care, which identified that one-third of patients experience delirium at the time of admission to inpatient palliative care units.

-   A formal risk of bias assessment of all studies revealed only one study with an overall low risk of bias. Substantial variability in delirium diagnostic and screening practices may contribute to significant bias in studies of delirium.

**Implications for practice, theory, or policy**

-   This review illustrates that delirium is highly prevalent across all palliative care settings, with one-third of patients experiencing delirium at the time of admission to acute palliative care.

-   The timely and accurate recognition of delirium both in clinical practice and in future research studies is crucial.

-   The review also identifies a gap in knowledge with respect to optimal delirium screening and diagnostic practices and provides a foundation on which research can be built.

Introduction {#section7-0269216319854944}
============

Delirium is an acute, complex, neurocognitive syndrome that commonly complicates medical illness. It is associated with impaired decision making and often causes significant distress to patients and their caregivers.^[@bibr1-0269216319854944][@bibr2-0269216319854944]--[@bibr3-0269216319854944]^ Across health care settings, delirium is known to contribute to increased patient morbidity and mortality^[@bibr4-0269216319854944],[@bibr5-0269216319854944]^ and is associated with longer hospital stays and increased health care costs.^[@bibr6-0269216319854944],[@bibr7-0269216319854944]^ Delirium frequently occurs in association with acute, often reversible, precipitating events such as infection and dehydration. In the palliative care population, these precipitating events are often superimposed on an underlying vulnerability that accompanies advanced disease. In addition to contributing to patient and caregiver distress, delirium frequently necessitates inpatient admission for care or complicates the care of an existing inpatient. In some cases, this may progress to a terminal, refractory delirium at end of life.^[@bibr8-0269216319854944]^ Although delirium is highly prevalent in palliative care settings, its occurrence is often not recognized and is poorly documented.^[@bibr9-0269216319854944],[@bibr10-0269216319854944]^

Standard consensus criteria such as the *International Classification of Diseases* (ICD)^[@bibr11-0269216319854944]^ and *Diagnostic and Statistical Manual of Mental Disorders* (*DSM*)^[@bibr12-0269216319854944]^ exist to aid physicians in the diagnosis of delirium. There have been multiple editions and updates of these gold standard criteria to reflect diagnostic advances. The original (*DSM*-*I*) and the most recent (*DSM*-*5*) editions were published in 1980 and 2013, respectively. Various tools have been developed to operationalize these criteria, particularly those of *DSM*, and facilitate delirium diagnosis and screening in clinical practice. Although many of these tools, such as the Confusion Assessment Method (CAM),^[@bibr13-0269216319854944]^ are validated in palliative care settings, no clear consensus exists as to the superior tool or the optimal frequency of delirium assessments. Consequently, the utility of these tools in clinical practice remains highly variable.^[@bibr14-0269216319854944][@bibr15-0269216319854944]--[@bibr16-0269216319854944]^

Delirium can be further classified into psychomotor subtypes such as hypoactive, hyperactive, and mixed (both hypo- and hyperactive features).^[@bibr17-0269216319854944],[@bibr18-0269216319854944]^ Normal (no psychomotor disturbance) subtype^[@bibr19-0269216319854944]^ and subsyndromal delirium^[@bibr20-0269216319854944]^ (the presence of some features of delirium while not clinically meeting diagnostic criteria) have also been described. Researchers have posited that hypoactive delirium, while common, is largely underdiagnosed, particularly due to overlapping clinical similarities with dementia and depression.^[@bibr21-0269216319854944],[@bibr22-0269216319854944]^ Thus, the importance of screening for delirium and the use of both clear documentation and diagnostic tools are considered pivotal.^[@bibr15-0269216319854944]^

Past reviews of delirium and its assessment in palliative care have examined the incidence and prevalence rates of delirium in this population.^[@bibr8-0269216319854944],[@bibr23-0269216319854944],[@bibr24-0269216319854944]^ Previously, a systematic review with eight included studies reported incidence and prevalence data from exclusively acute inpatient palliative care settings.^[@bibr8-0269216319854944]^ However, the palliative care context and population is not limited to the inpatient palliative care setting, and patients are often managed by specialist palliative care clinicians and generalists in both inpatient and outpatient settings. Currently, our awareness of how the incidence, prevalence, and clinical manifestations of delirium vary across these care settings is limited.^[@bibr25-0269216319854944]^ A formal knowledge synthesis of these domains will guide screening and diagnosis, in addition to identifying potential areas in which to focus future preventive and management strategies.

Following an initial scoping review of delirium in palliative care settings,^[@bibr26-0269216319854944]^ we undertook a systematic review with the aims of (1) estimating the incidence and prevalence of delirium in the adult palliative care population across health care settings, and (2) determining whether the incidence or prevalence of delirium varies by the clinical setting, the psychomotor sub-classification of delirium, patient factors, the proximity to death, delirium diagnostic criteria, study methodology, or study duration.

Methods {#section8-0269216319854944}
=======

This systematic review protocol was developed using the Joanna Briggs Institute Guide for conducting a systematic review of incidence and prevalence data.^[@bibr27-0269216319854944]^ Data are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.^[@bibr28-0269216319854944]^ The protocol was prospectively registered with PROSPERO.^[@bibr29-0269216319854944]^

Search strategy {#section9-0269216319854944}
---------------

The comprehensive search strategy consisted of peer-reviewed articles obtained from MEDLINE, EMBASE, CENTRAL, PsycINFO, and CINAHL electronic databases. It was validated by performing a Peer Review of the Electronic Search Strategy (PRESS), and records were initially retrieved on 21 November 2017 and updated on 15 March 2019. The search was limited to articles published after 1980, as no standardized diagnostic criteria for delirium existed prior to *DSM*-*I*. A hand-search of reference lists from included studies was also performed. In the search strategy, Medical Subheadings (MeSH) captured "delirium" and "palliative care" and their associated derivatives ([Supplemental Table 1](https://journals.sagepub.com/doi/suppl/10.1177/0269216319854944)). More specific epidemiological terms such as "incidence" and "prevalence" were not used to ensure inclusion of a wider scope of articles in primary screening.

Study selection {#section10-0269216319854944}
---------------

Titles, abstracts, and full texts of studies identified through the literature search were uploaded into DistillerSR software.^[@bibr30-0269216319854944]^ Two reviewers (P.G.L. and C.L.W.) independently performed title and abstract (Level 1) and full-text (Level 2) screening to determine study eligibility. Studies that did not meet a priori eligibility criteria were excluded, and the single best reason for exclusion at Level 2 screening was recorded. Conflicts at Level 1 and Level 2 screening were discussed and resolved without optional third-party arbitration.

Cross-sectional, cohort, nested-case control and experimental studies were included if they contained relevant epidemiological data on adult patients with delirium in any palliative care setting (as defined by Lawlor et al.^[@bibr26-0269216319854944]^). Studies were excluded if they did not use standard delirium diagnostic criteria (such as the *DSM*) or a validated diagnostic tool (such as the CAM), if they were published prior to 1980, or if they focused on alcohol withdrawal delirium. Studies performed in the post-operative and intensive care unit settings were also excluded, as were studies published in a language other than English and studies for which full text was unavailable.

Data extraction and risk of bias assessment {#section11-0269216319854944}
-------------------------------------------

Two reviewers (P.G.L. and C.L.W.) independently extracted general study and population characteristics, settings, and relevant epidemiological data from included studies using predesigned and piloted forms in DistillerSR software.^[@bibr30-0269216319854944]^ A risk of bias tool was developed to examine the potential selection, detection, attrition, and analytic biases specific to the unique nature of studies focused on delirium in palliative care populations ([Supplemental Table 2](https://journals.sagepub.com/doi/suppl/10.1177/0269216319854944)). This tool was also integrated into DistillerSR software, and each study underwent dual, independent assessment for risk of bias. Included studies were also assessed for applicability to the general palliative care population.

Data analyses/reporting {#section12-0269216319854944}
-----------------------

Incidence and prevalence data were pooled when heterogeneity between studies was minimal or could not be explained by clinical or methodological differences. Cochrane *Q* and *I*² values were used to quantify heterogeneity in addition to the χ² test for its statistical significance. A random effects model was used to formally generate pooled estimates of the point prevalence of delirium in inpatient palliative care units. When meta-analyses were not possible, incidence and prevalence data were synthesized narratively and presented as median summary estimates and associated range.

Results {#section13-0269216319854944}
=======

Selection of relevant studies {#section14-0269216319854944}
-----------------------------

The initial search strategy identified 3031 records, with another three records identified via handsearching. The updated literature search on 15 March 2019 identified an additional 707 records published up to 31 December 2018. The sequential processes of record identification, screening, and data extraction are summarized in the PRISMA diagram ([Figure 1](#fig1-0269216319854944){ref-type="fig"}). After the removal of duplicates, 2596 records were subject to title and abstract screening, and 153 of these underwent full-text screening. Of the 111 studies excluded during full-text review, 31 did not employ standard delirium diagnostic criteria and 22 were excluded as the investigational intent of the paper did not allow for epidemiological data to be obtained. One record lacked sufficient information to determine eligibility, and five were published in a language other than English. Full text was unavailable for 28 records. Duplicate study populations were used in five studies, and in these cases, the first published studies were included in the review and the remaining studies excluded. Ultimately, 42 studies met the eligibility criteria for study inclusion ([Supplemental Table 3](https://journals.sagepub.com/doi/suppl/10.1177/0269216319854944)).

![PRISMA flowchart of studies included in systematic review.](10.1177_0269216319854944-fig1){#fig1-0269216319854944}

Study demographics {#section15-0269216319854944}
------------------

An aggregate summary of the 42 included studies is shown in [Table 1](#table1-0269216319854944){ref-type="table"}, and individualized study summaries are available in [Supplementary Table 3](https://journals.sagepub.com/doi/suppl/10.1177/0269216319854944). The included studies originated from 13 different countries, with the majority (*n* = 20) from North America. Twenty-six studies were conducted in a single-center, specialist palliative care unit, based in a hospital (*n* = 12), a cancer center (*n* = 7) or a residential hospice (*n* = 7). Of the remaining studies, most (*n* = 7) involved inpatient medical or oncology patients in which a specialist palliative care team was consulted. Three studies were based in the community.

###### 

Care settings of included records.

![](10.1177_0269216319854944-table1)

  Study characteristics                                                                                                                                                                                                                                                                                                                               Number of studies, *n* = 42 (%)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Geographic region                                                                                                                                                                                                                                                                                                                                   
   USA^[@bibr31-0269216319854944][@bibr32-0269216319854944][@bibr33-0269216319854944][@bibr34-0269216319854944][@bibr35-0269216319854944][@bibr36-0269216319854944][@bibr37-0269216319854944][@bibr38-0269216319854944][@bibr39-0269216319854944][@bibr40-0269216319854944][@bibr41-0269216319854944]--[@bibr42-0269216319854944]^                    12
   Canada^[@bibr43-0269216319854944][@bibr44-0269216319854944][@bibr45-0269216319854944][@bibr46-0269216319854944][@bibr47-0269216319854944][@bibr48-0269216319854944][@bibr49-0269216319854944]--[@bibr50-0269216319854944]^                                                                                                                         8
   Italy^[@bibr51-0269216319854944][@bibr52-0269216319854944][@bibr53-0269216319854944]--[@bibr54-0269216319854944]^                                                                                                                                                                                                                                  4
   UK^[@bibr55-0269216319854944][@bibr56-0269216319854944]--[@bibr57-0269216319854944]^                                                                                                                                                                                                                                                               3
   Japan^[@bibr58-0269216319854944][@bibr59-0269216319854944]--[@bibr60-0269216319854944]^                                                                                                                                                                                                                                                            3
   Australia^[@bibr61-0269216319854944],[@bibr62-0269216319854944]^                                                                                                                                                                                                                                                                                   2
   Ireland^[@bibr63-0269216319854944],[@bibr64-0269216319854944]^                                                                                                                                                                                                                                                                                     2
   South Korea^[@bibr65-0269216319854944],[@bibr66-0269216319854944]^                                                                                                                                                                                                                                                                                 2
   Germany^[@bibr67-0269216319854944]^                                                                                                                                                                                                                                                                                                                1
   Hong Kong^[@bibr68-0269216319854944]^                                                                                                                                                                                                                                                                                                              1
   Belgium^[@bibr69-0269216319854944]^                                                                                                                                                                                                                                                                                                                1
   Taiwan^[@bibr70-0269216319854944]^                                                                                                                                                                                                                                                                                                                 1
   Turkey^[@bibr71-0269216319854944]^                                                                                                                                                                                                                                                                                                                 1
   Multiple countries^[@bibr72-0269216319854944]^                                                                                                                                                                                                                                                                                                     1
  Care setting                                                                                                                                                                                                                                                                                                                                        
   Single unit palliative care                                                                                                                                                                                                                                                                                                                        
    Hospital-based^[@bibr46-0269216319854944],[@bibr53-0269216319854944],[@bibr54-0269216319854944],[@bibr59-0269216319854944],[@bibr62-0269216319854944],[@bibr65-0269216319854944][@bibr66-0269216319854944][@bibr67-0269216319854944][@bibr68-0269216319854944][@bibr69-0269216319854944][@bibr70-0269216319854944]--[@bibr71-0269216319854944]^   12 (28)
    Hospice-based^[@bibr33-0269216319854944],[@bibr34-0269216319854944],[@bibr43-0269216319854944],[@bibr55-0269216319854944],[@bibr61-0269216319854944],[@bibr63-0269216319854944],[@bibr64-0269216319854944]^                                                                                                                                       7 (17)
    Cancer center--based^[@bibr32-0269216319854944],[@bibr35-0269216319854944],[@bibr37-0269216319854944],[@bibr40-0269216319854944],[@bibr50-0269216319854944],[@bibr52-0269216319854944],[@bibr72-0269216319854944]^                                                                                                                                7 (17)
   \>1 inpatient palliative care setting^[@bibr44-0269216319854944]^                                                                                                                                                                                                                                                                                  1 (2)
   Other palliative care settings                                                                                                                                                                                                                                                                                                                     
    Community palliative care^[@bibr31-0269216319854944],[@bibr38-0269216319854944],[@bibr48-0269216319854944]^                                                                                                                                                                                                                                       3 (7)
    Medical/Oncologyinpatients^[@bibr36-0269216319854944],[@bibr41-0269216319854944],[@bibr42-0269216319854944],[@bibr47-0269216319854944],[@bibr49-0269216319854944],[@bibr56-0269216319854944],[@bibr60-0269216319854944]^                                                                                                                          7 (17)
    Both inpatient and outpatient settings^[@bibr39-0269216319854944],[@bibr51-0269216319854944]^                                                                                                                                                                                                                                                     2 (5)
    Other care settings^[@bibr45-0269216319854944],[@bibr57-0269216319854944],[@bibr58-0269216319854944]^                                                                                                                                                                                                                                             3 (7)

Among the 42 included studies, some described epidemiological information in more than one care setting.^[@bibr45-0269216319854944],[@bibr57-0269216319854944],[@bibr58-0269216319854944]^ As a result, data from 46 discrete study populations were obtained ([Table 2](#table2-0269216319854944){ref-type="table"}), with a total of 16,491 palliative care patients included across all studies. Of the included study populations, 34 had \>90% of the study subjects with a cancer diagnosis; another 7 had a heterogeneous mix of cancer and non-cancer diagnoses. One study population focused solely on patients with AIDS. The majority of study populations were not selected for age or gender. Patients with pre-existing cognitive impairment (presence of underlying dementia) were included in 17 study populations and excluded in 4 study populations. In 25 of the study populations, pre-existing cognitive impairment status (presence or absence of dementia) was not reported.

###### 

Study demographics of included study populations (total 46 distinct study populations described in 42 included studies).

![](10.1177_0269216319854944-table2)

  Study population characteristics          Number of distinct study populations, *n* = 46 (%)
  ----------------------------------------- ----------------------------------------------------
  Palliative care diagnosis                 
   ⩾90% cancer                              34 (74)
   Mix of cancer and non-cancer diagnoses   7 (15)
   AIDS                                     1 (2)
   Other                                    1 (2)
   Not reported/Unknown                     3 (7)
  Patient demographics                      
   Age                                      
    Age mixed                               41 (89)
    Not reported/Unknown                    5 (11)
   Gender                                   
    Gender mixed                            42 (91)
    ⩾80% male                               1 (2)
    ⩾80% female                             0
    Not reported/Unknown                    3 (7)
   Pre-existing cognitive impairment        
    Included in study                       17 (37)
    Excluded from study                     4 (9)
    Unknown or not assessed                 25 (55)

Delirium diagnosis {#section16-0269216319854944}
------------------

A total of 17 different delirium diagnostic tools were used among the 42 included studies: 27 studies used more than one tool to diagnose delirium and 15 studies relied on a single tool. Of the diagnostic tools used, the CAM was most frequently used (*n* = 17), followed by *DSM*-*IV* (*n* = 10). *DSM* criteria of any kind (*DSM*-*III* to *DSM-5*) were used in 21 studies. The epidemiological data obtained from each diagnostic tool are shown in [Figure 2](#fig2-0269216319854944){ref-type="fig"}.

![Delirium incidence and prevalence rate by diagnostic tool used.\
MDAS: Memorial Delirium Assessment Scale; *DSM: Diagnostic and Statistical Manual of Mental* Disorders; CAM: Confusion Assessment Method; BCS: Bedside Confusion Scale; Nu-DESC: Nursing Delirium Screening Scale; ICD: *International Classification of Diseases*.](10.1177_0269216319854944-fig2){#fig2-0269216319854944}

Assessment of epidemiological data {#section17-0269216319854944}
----------------------------------

The incidence and prevalence of delirium in studies across various care settings are depicted in [Figure 3](#fig3-0269216319854944){ref-type="fig"}.

![Incidence and prevalence of delirium across palliative care settings.\
Prev: prevalence.](10.1177_0269216319854944-fig3){#fig3-0269216319854944}

### Inpatient palliative care settings {#section18-0269216319854944}

Epidemiological data were extracted from studies in 23 inpatient palliative care settings; 12 were hospital-based,^[@bibr46-0269216319854944],[@bibr53-0269216319854944],[@bibr54-0269216319854944],[@bibr59-0269216319854944],[@bibr62-0269216319854944],[@bibr65-0269216319854944][@bibr66-0269216319854944][@bibr67-0269216319854944][@bibr68-0269216319854944][@bibr69-0269216319854944][@bibr70-0269216319854944]--[@bibr71-0269216319854944]^ 7 were in inpatient hospices,^[@bibr33-0269216319854944],[@bibr34-0269216319854944],[@bibr43-0269216319854944],[@bibr55-0269216319854944],[@bibr61-0269216319854944],[@bibr63-0269216319854944],[@bibr64-0269216319854944]^ and 7 were in acute palliative care units within a cancer center.^[@bibr32-0269216319854944],[@bibr35-0269216319854944],[@bibr37-0269216319854944],[@bibr40-0269216319854944],[@bibr50-0269216319854944],[@bibr52-0269216319854944],[@bibr72-0269216319854944]^ The median (range) cumulative incidence of delirium in inpatient palliative care units during the entire admission was 29% (7%--45%).^[@bibr37-0269216319854944],[@bibr44-0269216319854944],[@bibr46-0269216319854944],[@bibr55-0269216319854944],[@bibr57-0269216319854944],[@bibr66-0269216319854944]^ Length of stay in relation to cumulative incidence was represented by a wide range of median values. Delirium incidence rate during admission was estimated in one study at 25.4/1000 person-days.^[@bibr44-0269216319854944]^ The point prevalence of delirium on admission was recorded in 18 different study populations^[@bibr35-0269216319854944],[@bibr37-0269216319854944],[@bibr40-0269216319854944],[@bibr44-0269216319854944],[@bibr46-0269216319854944],[@bibr52-0269216319854944][@bibr53-0269216319854944][@bibr54-0269216319854944]--[@bibr55-0269216319854944],[@bibr57-0269216319854944],[@bibr59-0269216319854944],[@bibr61-0269216319854944],[@bibr63-0269216319854944],[@bibr64-0269216319854944],[@bibr66-0269216319854944],[@bibr68-0269216319854944],[@bibr71-0269216319854944],[@bibr72-0269216319854944]^ with a median (range) of 32% (6.6%--73%). The median (range) period prevalence during the course of an entire inpatient admission was 60% (19%--88%, *n* = 11 studies, 12 distinct populations),^[@bibr33-0269216319854944],[@bibr37-0269216319854944],[@bibr44-0269216319854944][@bibr45-0269216319854944]--[@bibr46-0269216319854944],[@bibr50-0269216319854944],[@bibr55-0269216319854944],[@bibr67-0269216319854944],[@bibr70-0269216319854944][@bibr71-0269216319854944]--[@bibr72-0269216319854944]^ noting again that a wide range of median and mean lengths of stays were reported.

### Inpatient settings involving palliative care consultation {#section19-0269216319854944}

Of the seven studies in inpatient settings where palliative care services were consulted, five were conducted in general medical inpatients^[@bibr41-0269216319854944],[@bibr47-0269216319854944],[@bibr49-0269216319854944],[@bibr60-0269216319854944],[@bibr56-0269216319854944]^ and two in oncology inpatients.^[@bibr36-0269216319854944],[@bibr42-0269216319854944]^ The cumulative incidence of delirium was reported in one study as 16.5%.^[@bibr49-0269216319854944]^ The median (range) point prevalence of delirium reported at the time of initial palliative care consultation was 25% (9%--57%).^[@bibr36-0269216319854944],[@bibr41-0269216319854944],[@bibr47-0269216319854944],[@bibr56-0269216319854944],[@bibr60-0269216319854944]^

### Community palliative care {#section20-0269216319854944}

Point prevalence of delirium on initial community assessment was reported in the range of 4%--12% in two studies.^[@bibr38-0269216319854944],[@bibr48-0269216319854944]^ The period prevalence of delirium throughout the course of community follow-up (median length of 81 days) was 55% in one study.^[@bibr38-0269216319854944]^

### Prior to death {#section21-0269216319854944}

In the inpatient palliative care setting, the median (range) period prevalence of delirium prior to death was 75% (58%--88%) in four distinct study populations (reported in three studies).^[@bibr45-0269216319854944],[@bibr50-0269216319854944],[@bibr68-0269216319854944]^ In two studies of the inpatient setting with palliative care consultation, delirium at end of life was reported in the range of 78%--85%;^[@bibr42-0269216319854944],[@bibr45-0269216319854944]^ whereas in the community setting, a lower range of 42.5%--44% was reported, also in two studies.^[@bibr31-0269216319854944],[@bibr38-0269216319854944]^ Of note, there was variability in the time of delirium assessment prior to death. While some studies reported delirium prevalence at the time of death^[@bibr50-0269216319854944]^ or in the last week of life,^[@bibr31-0269216319854944],[@bibr68-0269216319854944]^ other studies did not clarify the timing of assessments in the "prior to death" interval.^[@bibr38-0269216319854944],[@bibr45-0269216319854944]^

Risk of bias {#section22-0269216319854944}
============

The results of the risk of bias and validity assessments are presented in [Figure 4](#fig4-0269216319854944){ref-type="fig"}. Remarkably, only one study had a low risk of bias as determined by the risk of bias tool ([Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/0269216319854944)). The remaining studies were rated as having moderate (*n* = 22), high (*n* = 11), and critical (*n* = 8) risk of bias. The most frequent area in which risk of bias was introduced was detection (delirium diagnosis), with 13 studies (33%) scoring high risk of bias in this area. Study population findings were considered applicable to the general adult palliative care population, as defined in the study protocol,^[@bibr29-0269216319854944]^ in 32 studies (76%).

![Risk of bias of included studies and applicability to defined study population. Results of risk of bias and applicability assessment as outlined in [Supplemental Table 2](https://journals.sagepub.com/doi/suppl/10.1177/0269216319854944).](10.1177_0269216319854944-fig4){#fig4-0269216319854944}

Meta-analyses {#section23-0269216319854944}
=============

Fourteen studies were included in meta-analyses. All of these studies reported the point prevalence of delirium upon admission to an inpatient palliative care unit, consisted of \>90% of patients with a cancer diagnosis, and were not selected for age or gender. The relevant inpatient palliative care units consisted of inpatient hospices (*n* = 4), palliative care units in a tertiary care hospital (*n* = 6), and palliative care units in a cancer center (*n* = 4). Due to insufficient reporting of other pre-specified covariate data and limited number of studies in the meta-analysis, further exploration of heterogeneity was not possible. Considering this heterogeneity as unexplained, pooled point prevalence across the included studies yielded a point prevalence estimate of 35% (95% confidence interval (CI) = 0.29--0.40) at inpatient admission, with high heterogeneity between studies (*I*^2^ = 85%) ([Figure 5](#fig5-0269216319854944){ref-type="fig"}). Inter-study heterogeneity was not secondary to care setting or overall risk of bias. When outlier studies^[@bibr43-0269216319854944],[@bibr63-0269216319854944]^ were removed from meta-analyses, there was minimal change in pooled point prevalence, but some improvement in overall heterogeneity was noted (point prevalence = 34%, 95% CI = 0.30--0.39, *I*^2^ = 74%, *n* = 12 studies).

![Meta-analyses of delirium point prevalence at the time of admission to inpatient palliative care units (*n* = 14 studies, 2502 total patients).](10.1177_0269216319854944-fig5){#fig5-0269216319854944}

Delirium subtypes {#section24-0269216319854944}
-----------------

The psychomotor subtypes of delirium were reported in 11 studies, with median rates (range) of hypoactive and hyperactive delirium reported as 39% (22%--86%) and 14% (0%--33%), respectively.^[@bibr35-0269216319854944][@bibr36-0269216319854944]--[@bibr37-0269216319854944],[@bibr57-0269216319854944],[@bibr61-0269216319854944],[@bibr65-0269216319854944][@bibr66-0269216319854944][@bibr67-0269216319854944]--[@bibr68-0269216319854944],[@bibr70-0269216319854944],[@bibr71-0269216319854944]^ Mixed delirium was reported in 10 distinct study populations in nine studies, with a median prevalence (range) of 23% (10%--45%).^[@bibr36-0269216319854944],[@bibr37-0269216319854944],[@bibr57-0269216319854944],[@bibr65-0269216319854944][@bibr66-0269216319854944][@bibr67-0269216319854944]--[@bibr68-0269216319854944],[@bibr70-0269216319854944],[@bibr71-0269216319854944]^ The prevalence of subsyndromal delirium was reported in one study population as 9.8%.^[@bibr61-0269216319854944]^ One study also reported "level of alertness" as normal in 46% of delirious patients.^[@bibr35-0269216319854944]^

Discussion {#section25-0269216319854944}
==========

Main findings of the study {#section26-0269216319854944}
--------------------------

Drawing from a richer pool of estimates, this study updated and expanded on the 2013 systematic review by Hosie et al., which included eight studies and examined the incidence and prevalence of delirium in patients specifically admitted to inpatient palliative care units and hospices.^[@bibr8-0269216319854944]^ The inclusion of 34 additional studies in the current systematic review not only generates updated estimates in inpatient palliative care patients but also identifies novel information with regard to the occurrence rates of delirium in general inpatient settings and in the community setting. In addition, this review includes a formal risk of bias assessment for all studies. To our knowledge, it is the first systematic review to formally conduct a risk of bias assessment as it pertains to the diagnosis and monitoring of delirium in palliative care settings. Moreover, the included studies allowed for a limited meta-analysis of their data, identifying a pooled point prevalence of delirium on admission to inpatient palliative care units. These findings enhance our knowledge of the epidemiological burden of delirium across multiple care settings. Such estimates will in turn prove useful in informing the design of future primary research studies, particularly regarding sample size estimation.

Ultimately, the results of this study demonstrate that delirium is highly prevalent across all palliative care settings. In general, the prevalence of delirium tends to be lowest at the time of admission, rises during follow-up, and is most highly prevalent prior to death, with a rate reported up to 88%. Pooled prevalence estimates indicate that one-third (35%) of patients are diagnosed with delirium at the time of admission to inpatient palliative care. These estimates are of great relevance, as delirium is often under-recognized and under-reported.^[@bibr9-0269216319854944],[@bibr10-0269216319854944]^ It highlights the potential need for delirium screening and the importance of timely recognition of delirium in palliative care.

Interestingly, the overall prevalence of delirium in the community appears to be lower than in inpatient settings. This may relate to a more de-institutionalized, familiar, and less disorienting setting of care. In the community, there tends to be less medical intervention (such as intravenous lines and catheters), and accepted non-pharmacological prevention strategies (such as maintaining sleep hygiene and limiting noise)^[@bibr15-0269216319854944],[@bibr73-0269216319854944]^ are often more easily prioritized and achieved. In addition, patients managed at home may be less complex, requiring lower doses of opioids and other medications. Alternatively, the lower rate of delirium in the community may suggest that delirium prompts a crisis admission to hospital or inpatient hospice and that increasing care burdens and behavioral challenges make staying at home a less viable option for delirious patients and their caregivers.^[@bibr74-0269216319854944]^

Strengths and limitations of the study {#section27-0269216319854944}
--------------------------------------

Although this study presents novel information with regard to delirium rates across multiple care settings, there are some important limitations. Contrary to the 2013 systematic review by Hosie et al.,^[@bibr8-0269216319854944]^ this review included studies in which the primary study aim was not to examine the incidence or prevalence of delirium but nonetheless obtain epidemiological data from a representative palliative care population using validated delirium diagnostic tools. This may result in a wider range of reported delirium occurrence rates, as the methodological rigor pertaining to delirium diagnosis is increasingly varied when compared to the 2013 systematic review. There are also challenges with the reporting of epidemiological data in these studies, as the majority report a proportion of patients with delirium or discrete numerical rate without confidence intervals. In addition, in the current review, there is significant heterogeneity among the included studies with respect to diagnostic tools, assessment intervals, and the reporting of longitudinal data. For example, the length of patient stays was reported as a wide range of medians and means, with some studies not reporting length of stay at all. This heterogeneity among studies significantly limited further pooling of delirium epidemiological data, and apart from one pooled estimate, epidemiological data in this review are crudely summarized using median figures with associated ranges rather than formally pooled data.

Fourteen studies were included in the meta-analyses of point prevalence data at the time of admission to inpatient palliative care units. These studies were deemed sufficiently homogeneous for inclusion with regard to care setting and patient demographic information. However, meta-analyses revealed a high *I*^2^ value (85%), suggesting that additional variables are contributing to inter-study heterogeneity. This heterogeneity is potentially due to variability among diagnostic tools used, screening practices and training of team members, as well as important patient factors such as performance status, risk factors for delirium (such as pre-existing cognitive impairment), and goals of care. Unfortunately, there was inconsistent reporting of these covariate factors, which limited further assessment.

The ability to perform further meta-analyses on gathered data is limited by the higher rates of bias across the included studies. Ultimately, only one study scored a low risk of bias in all potential areas.^[@bibr44-0269216319854944]^ Bias appeared to be introduced most commonly during the diagnosis of delirium (detection bias); however, concerns with selection bias were also highlighted. Only 10 of the included studies scored low with respect to selection bias.^[@bibr43-0269216319854944],[@bibr44-0269216319854944],[@bibr46-0269216319854944],[@bibr57-0269216319854944],[@bibr59-0269216319854944],[@bibr62-0269216319854944],[@bibr64-0269216319854944],[@bibr66-0269216319854944],[@bibr68-0269216319854944],[@bibr71-0269216319854944]^ In these studies, demographics such as age, gender, and primary diagnoses were reported, in addition to disclosing the pre-existing cognitive impairment status of the study population. As underlying dementia is a strong predisposing factor in the development of delirium,^[@bibr75-0269216319854944],[@bibr76-0269216319854944]^ it ought to be considered when evaluating the epidemiological data presented in each study population. Neglecting to adjust for this confounding variable may contribute to falsely higher rates of delirium in some study populations. The lack of consistently reported cognitive impairment data identifies a need to determine the strength of pre-existing cognitive impairment as a risk factor for the occurrence of delirium in palliative care.

What this study adds {#section28-0269216319854944}
--------------------

This review provides a foundation on which to plan and design future delirium studies: for example, incidence data are critical in informing the design of prevention studies. It again highlights a previously identified gap in knowledge with respect to the role of delirium screening and diagnostic strategies.^[@bibr14-0269216319854944],[@bibr15-0269216319854944],[@bibr25-0269216319854944]^ Among the 42 included studies, a wide variety of screening and diagnostic practices were employed. Nearly all included studies (*n* = 36) performed some form of screening for delirium; however, the frequency of screening and screening tools varied substantially, with a total of 10 different screening tools used across the 36 studies.^[@bibr31-0269216319854944],[@bibr33-0269216319854944][@bibr34-0269216319854944][@bibr35-0269216319854944][@bibr36-0269216319854944][@bibr37-0269216319854944][@bibr38-0269216319854944][@bibr39-0269216319854944][@bibr40-0269216319854944]--[@bibr40-0269216319854944],[@bibr42-0269216319854944][@bibr43-0269216319854944][@bibr44-0269216319854944][@bibr45-0269216319854944][@bibr46-0269216319854944][@bibr47-0269216319854944][@bibr48-0269216319854944][@bibr49-0269216319854944][@bibr50-0269216319854944]--[@bibr51-0269216319854944],[@bibr53-0269216319854944][@bibr54-0269216319854944][@bibr55-0269216319854944][@bibr56-0269216319854944]--[@bibr57-0269216319854944],[@bibr59-0269216319854944],[@bibr61-0269216319854944][@bibr62-0269216319854944][@bibr63-0269216319854944]--[@bibr64-0269216319854944],[@bibr66-0269216319854944][@bibr67-0269216319854944][@bibr68-0269216319854944][@bibr69-0269216319854944][@bibr70-0269216319854944][@bibr71-0269216319854944]--[@bibr72-0269216319854944]^

This illustrates a need to further evaluate delirium diagnostic and screening strategies in palliative care settings, including their comparative metrics and burden, as well as their validity compared to a reference standard. A systemic review of the utility of delirium diagnostic and screening tools in palliative care settings would help to inform both the development of clinical practice guidelines on delirium assessment and the need for further primary studies.

Conclusion {#section29-0269216319854944}
==========

This systematic review has revealed that delirium is highly prevalent in palliative care across all care settings. Data have shown that a median (range) of 60% of patients developed delirium throughout an admission to inpatient palliative care, and a meta-analysis has shown that 35% of patients were delirious at the time of admission to inpatient palliative care. In the inpatient consultative setting, the median (range) point prevalence of delirium was found to be 25% (9%--57%) at the time of inpatient palliative care consult. Overall, delirium appears to be less prevalent in the community setting, with the point prevalence reported as 4%--12% at the time of community palliative care consultation. In all care settings, delirium is most prevalent prior to death. Hypoactive delirium is the most prevalent psychomotor subtype, followed by mixed delirium. This review also demonstrates the challenges encountered in knowledge synthesis, particularly in relation to the multiplicity of validated delirium diagnostic tools and varied clinical assessment practices, thus highlighting a need for increasingly rigorous and unbiased primary studies of delirium in the various clinical contexts and settings in which palliative care is delivered. Ultimately, the findings of this review provide a foundation on which future studies requiring the identification of delirium can be designed and planned.
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